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Abstract 
Background: Olfactomedin is a member of a diverse group of extracellular matrix 25 
proteins important for neuronal growth.  Recent microarray studies identified 
olfactomedin (Olfm) as one of the down-regulated transcripts in receptive 
endometrium for embryo attachment and implantation. However, the underlying 
molecular mechanisms that govern Olfm expression and its effect on embryo 
attachment and implantation remain unknown. 30 
Objectives: To study the expression of Olfm in the human endometrium by real-time 
PCR and immunohistochemistry, and the function of Olfm in trophoblast-endometrial 
cell attachment.  
Setting: University reproduction unit and laboratory. 
Intervention(s): Real-time PCR, Western blotting and immunohistochemistry on 35 
human endometrial biopsies from natural and ovarian stimulated cycles. In vitro 
spheroids-endometrial cells co-culture study. 
Results: Human endometrial Olfm-1 and Olfm-2 transcripts decreased significantly 
from the proliferative to the secretory phases of the menstrual cycle. Olfm protein was 
strongly expressed in the luminal and glandular epithelium and moderately in the 40 
stromal cells of human endometria. Ovarian stimulation significantly decreased 
(p<0.05) the expression of endometrial Olfm-1 and -2 transcripts in patients receiving 
IVF treatment when compared with those in the natural cycle. Importantly, 
recombinant Olfm-1 suppressed JAr spheroids attachment onto Ishikawa cells and this 
was not associated with changes of β-catenin and E-cadherin expression in 45 
trophoblast and endometrial cells. 
Conclusion(s): Decreased expression of Olfm during the receptive phase of the 
endometrium may allow successful trophoblast attachment for implantation. 
 3 
Introduction 50 
The attachment of a preimplantation embryo onto the uteri endometrium initiates 
the establishment of pregnancy.  The endometrium is receptive to the implanting 
embryo only within a short period, termed the “Window of Implantation” (WOI), 
which lies between days 19–24 of the menstrual cycle in humans.  Recent 
microarray studies have identified a number of genes that are differentially regulated 55 
during the WOI.  In mice, the gene expression profiles of whole uterine tissue before 
and after implantation (Yoshioka et al., 2000), and between implantation and 
inter-implantation sites (Reese et al., 2001) has been studied.  Due to ethical reasons, 
similar studies in humans with embryos at the implantation site are not possible.  
However, four microarray studies (Carson et al., 2002; Kao et al., 2002; Borthwick et 60 
al., 2003; Riesewijk et al., 2003) compared the gene expression of the endometrium at 
the WOI with that at the proliferative phase or early secretory phase, and found 
differential expression of a large number of genes.  While these studies demonstrated 
the developmental complexity of the endometrium, there were only a few similarities 
between their results, in which only three genes (Dickkopf homolog 1, osteopontin 65 
and apolipoprotein D) were up-regulated and one gene (Olfactomedin, Olfm) was 
down-regulated (Horcajadas et al., 2004). Previously, we reported that 
down-regulation of endometrial olfactomedin-1 (Olfm-1) expression was found in 
patients receiving ovarian stimulation for IVF treatment (Liu et al., 2008). 
Olfm was first cloned from the olfactory mucus of Rana catesbeiana (Yokoe et 70 
al., 1993), and is a member of a diverse group of extracellular matrix proteins 
including the neural cell adhesion molecule, laminin, fibronectin and proteoglycans 
(Reichardt et al., 1991).  More than 100 known Olfm members have been discovered 
in various species (Zeng et al., 2005).  Molecular analysis has shown that Olfms are 
glycoproteins that can form stable polymers through interaction with the glycans of 75 
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the neighboring molecules (Yokoe et al., 1993).  An increasing number of proteins 
are found to contain an Olfm domain, including amassin in sea urchins, tiarin in 
amphibians, and noelin and myocilin/TIGR in vertebrates.  Although the biological 
functions of members in the Olfm family are not well understood, they are likely to be 
involved in the formation of the extracellular matrix (Karavanich et al., 1998). 80 
Clinically, an increased expression of Olfm-1 is associated with unexplained recurrent 
spontaneous abortion (Lee et al., 2007).  Forced expression of Olfm-1 in a human 
endometrial cell line inhibited cell growth and induced cell cycle arrest at the S and 
G2-M phases (Lee et al., 2007).  Yet, Olfm-1 transcript was down-regulated in 
endometrial cancer with uncontrolled cell proliferation (Wong et al., 2007).  A 85 
recently identified novel human Olfm-like protein-1 (hOLFML1), which contains an 
Olfm domain, enhances proliferation of the HeLa cells in vitro (Wan et al., 2008). 
Zebrafish Olfm-1 interacts with WIF-1, a secreted inhibitor of Wnt-signaling, and 
regulates retinal axon elongation in vivo (Nakaya et al., 2008).  Moreover, an 
Olfm-like glycoprotein, hOLF44, has been isolated and suggested to be involved in 90 
human placental and embryonic development (Zeng et al., 2004).  The widespread 
occurrence of Olfm-related proteins in vertebrates and invertebrates suggests that this 
family has functions of universal importance. 
In the present study, we hypothesized that Olfm is differentially expressed in the 
endometrium of a normal menstrual cycle and that it modulates implantation.  We 95 
aimed to determine the expression of Olfm transcripts in human endometria taken in 
natural and stimulated cycles, to correlate their expression with the hormonal status of 
the women, and to study the role of Olfm in regulating trophoblast attachment onto 
endometrial epithelial cells in vitro.
 5 
Methods and Materials 100 
Patients 
 Infertile women who attended the Assisted Reproduction Unit, The University 
of Hong Kong–Queen Mary Hospital for IVF treatment were recruited for this study.  
They had regular menstrual cycles, normal uterus and no significant intrauterine or 
ovarian abnormalities as determined by transvaginal ultrasonography.  Only women 105 
with regular menstrual cycles and male factor infertility who had not received any 
steroidal hormones for 2 months or more prior to the study and also agreed to the use 
of condoms for contraception during the study cycle were recruited for endometrial 
biopsies in the natural cycle (Liu et al., 2010).  The study protocol was approved by 
the Institutional Review Board of The University of Hong Kong/Hospital Authority 110 
Hong Kong West Cluster. Written informed consent was obtained from all patients 
prior to participation in the study. 
 Endometrial biopsies were taken from patients undergoing diagnostic 
laparoscopy for assessment of tubal patency from 2004 to 2005.  These samples 
were taken in different phases of the menstrual cycle including early-/mid-proliferate 115 
phase (Day 1-9, EPMP, n=8), late proliferate phase (Day 10-14, LP, n=8), early 
secretory phase (Day 15-18, ES, n=8), middle secretory phase (Day 19-23, MS, n=15), 
and late secretory phase (Day 24-28, LS, n=6).  The donors of these samples in 
different groups did not differ significantly (p>0.05) in terms of age and duration of 
infertility. 120 
 Human endometrial samples from the stimulated cycle were collected from 
early 2002 to December 2008.  The ovarian stimulation was carried out as described 
previously using the long protocol (Ng et al., 2000).  Endometrial biopsies in the 
stimulated cycles (n=32) were obtained seven days after the hCG injection (hCG+7), 
and endometrial biopsies in natural cycles (n=15) were taken on day LH+7 (7 days 125 
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after luteinizing hormone surge) as described previously (Liu et al., 2008).  Those 
patients were recruited when embryo transfer was not performed due to the failure of 
fertilization caused by male factors, absence of spermatozoa in testicular sperm 
extraction on the day of oocyte retrieval or when the serum E2 level 
was >20,000pmol/L on the day of hCG injection. 130 
 
Tissue Collection 
Biopsies were performed as an outpatient procedure from the fundal and upper 
part of the body of the uterus using the Pipelle device (CCD Laboratories, France). 
The biopsy specimen was snap-frozen in liquid nitrogen and was stored at -80º C until 135 
total RNA isolation was achieved.  Serum E2 and progesterone (P4) levels were also 
measured on the day of the biopsy by commercially available 
chemiluminescent-based immunoassay kits as reported previously (Ng et al., 2000). 
 
RNA extraction, reverse transcription and real-time PCR 140 
 Total RNAs from human endometrial biopsies were extracted using the 
Absolutely RNA Microprep Kit (Stratagene, La Jolla, CA) according to the 
manufacturer’s instructions.  RNA samples (300 ng) were reverse-transcribed into 
cDNA using TaqMan® Reverse Transcription Reagents (PE Applied Biosystems, 
Foster City, CA).  Multiplex real-time polymerase chain reaction using 18S as an 145 
internal control for the normalization of RNA loading was performed in a 20 μl 
reaction mixture with Assays-on-Demand Gene Expression Assay for human Olfm-1, 
-2, -3 and -4 (PE Applied Biosystems).  Samples from the mid-secretory phase were 
used as calibrators for different PCR experiments.  The human Olfm-1 
(Hs00255159_m1), Olfm-2 (Hs00608880_m1), Olfm-3 (Hs00379238_m1), Olfm-4 150 
(Hs00197437_m1), estrogen receptor-α (Hs00174860_m1), estrogen receptor-β 
 7 
(Hs00230957_m1) and ribosomal 18S (Hs99999901_s1) TaqMan probes were used 
(PE Applied Biosystems). 
 
Protein extraction and Western blotting 155 
 Total proteins from endometrial biopsies and cell lysates [Ishikawa, JAr and 
fallopian tube epithelial OE-E6/E7 (Lee et al., 2001) cells] were dissolved in RIPA 
solution (1X PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) 
containing protease inhibitors. The Olfm-1, β-catenin, E-cadherin protein expression 
was analyzed by Western blotting.  The membranes were probed with affinity 160 
purified rabbit anti-human Olfm polyclonal antibody (1:1000 dilution, Zymed Lab, 
Burlingame, CA) raised against Olfm-1 peptide (aa 246-259, 
C-YMDGYHNNRFVREY-NH2), mouse anti-E-cadherin (1:1000, Abcam, Cambridge, 
MA), or mouse anti-β-catenin (1:2500, BD Bioscience, San Jose, CA) in blocking 
solution overnight at 4oC. The anti-rabbit or anti-mouse secondary antibody 165 
conjugated with horseradish peroxidase (1:5000, GE Healthcare, Pittsburgh, PA) was 
used. Olfm-2 and Olfm-3 peptides (C-YMDGYYKGRRVLEF-NH2 and 
C-YMDSYTNNKIVREY-NH2, respectively) were synthesized (GenScript, 
Piscataway, NJ) and used to neutralize Olfm-1 antibody (5-fold excess) at 4oC for 4 
hours.  After thorough washing, the membrane was visualized by enhanced 170 
chemiluminescence reagent (Santa Cruz). To normalize the protein loading, the 
membranes were stripped and detected for β-actin using anti-β-actin antibody (Sigma, 
St Louis, MO). 
 
Production, purification and labeling of human recombinant Olfm (rhOlfm) 175 
 The full length Olfm-1 coding sequence was amplified from cDNA reverse 
transcribed from total RNA isolated from human endometrial epithelial cells by PCR 
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using the Expand Long Template PCR system with proof reading Taq DNA 
polymerase (Roche, Mannheim, Germany) and gene-specific primers (Forward: 
5’-CGGATCATATGCCAGGTCGTTGGAGGTGG-3’; Reverse: 5’-CATGCTCAGC 180 
CTACAACTCGTCGGAGCGGAT-3, restriction sites underlined’) containing NdeI 
and BlpI restriction sites, and cloned into a pET15b expression vector (Novagen, 
Gibbstown, NJ).  One positive clone was transformed into E. coli BL21 (DE3) RIL 
cells (Stratagene, La Jolla, CA), and human recombinant Olfm-1 (rhOlfm-1) protein 
was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 hrs at 185 
37oC.  rhOlfm-1 was purified using a protein refolding kit (Novagen, Gibbstown, NJ) 
as described previously (Lee et al., 2006).  The identity of the purified protein was 
confirmed by Western blotting and mass spectrometry analysis.  To determine the 
binding of rhOlfm-1 to the endometrial and trophoblast cells, 50 µg of the 
recombinant protein was labeled with the AlexaFluor® 488 Microscale Protein 190 
Labeling kit (Molecular Probes, Invitrogen, Carlsbad, CA) using the protocol 
described by the manufacturer.  Then, the cells were incubated with the medium 
containing the labeled recombinant protein (5 µg/ml) for 3 hrs and washed twice with 
PBS, and the signal was detected under a florescence microscope. 
 195 
Immunohistochemistry 
 Human endometrial biopsies were fixed in buffered formalin, embedded in 
paraffin, sectioned at 5 μm in thickness, and mounted on poly-lysine coated-slides. 
Tissue sections were de-paraffinized, which was followed by antigen retrieval using 
the Target Retrieval Solution (DakoCytomation, Carpinteria, CA) as previously 200 
described (Lee et al., 2006).  A rabbit anti-human Olfm polyclonal antibody (1:200), 
no primary antibody or an antibody pre-absorbed with the antigen/blocking peptide 
(Zymed Lab) was included.  Finally, positive signal was detected using 
 9 
3,3'-diaminobenzidine (DakoCytomation).  Nuclei were counter-stained with 
hematoxylin. The sections were observed with a Zeiss Axioskop microscope 205 
(Photometrics Sensys, Roper Scientific, Tuesoa, AZ) with bright-field optics. 
 
Spheroids-endometrial cell attachment assay 
Human choriocarcinoma cells (JAr, ATCC HTB-144) and endometrial 
adenocarcinoma cells (Ishikawa, ECACC 99040201) were cultured at 37oC in a 210 
humid atmosphere with 5% CO2.  Adhesion of choriocarcinoma JAr cells to 
endometrial Ishikawa cells was quantified using an adhesion assay as described (Hohn 
et al., 2000; Uchida et al., 2007; Liu et al., 2010) with modifications.  For the 
co-culture study, JAr cells were treated with 0.1-10 µg/ml Olfm-1, 5 µM methotrexate 
(MTX) as a positive control and 1 µg/ml BSA as a negative control for 48 hrs.  215 
Multi-cellular spheroids were generated by rotating the trypsinized cells at 4g force 
for 24 hrs.  The spheroids of sizes 60–200 µm were transferred onto the surface of a 
confluent monolayer of the Ishikawa cells pre-treated with Olfm-1 for 24 hrs.  The 
cultures were maintained in MEM medium with rhOlfm-1 for 1 hr at 37oC in a 
humidified atmosphere with 5% CO2. Non-adherent spheroids were removed by 220 
centrifugation at 10g for 10 min.  To study the effect of Olfm-1 on JAr cells only, the 
JAr cells were treated with rhOlfm-1 for 48 hrs before spheroid generation.  The 
spheroids were then co-cultured with the untreated Ishikawa cells for an hour. The 
effect of Olfm-1 on Ishikawa cells was studied by treating the cells with rhOlfm-1 for 
24 hrs before co-culture with untreated JAr spheroids for an hour. Attached spheroids 225 
were counted under a dissecting microscope, and expressed as the percentage of the 
total number of spheroids used (% adhesion). Photographs of the cultures were taken 
with a Nikon Eclipse TE300 inverted microscope (Nikon, Tokyo, Japan). 
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Statistical analysis 230 
 All the data were analyzed by statistical software (SigmaPlot 10.0 and 
SigmaStat 2.03; Jandel Scientific, San Rafael, CA).  The non-parametric analysis of 
variance on rank test for multiple comparisons followed by the Mann-Whitney U test 
was used when the data were not normally distributed.  A probability value <0.05 
was considered to be statistically significant.235 
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Results 
 
Expression of Olfms in human endometrium in the menstrual cycle 
Olfm has four known transcripts (Olfm-1, -2, -3 and -4) and their expressions in 
different phases of the menstrual cycle were studied by real-time PCR.  Olfm-1 and 240 
-2 transcripts were highly expressed in the proliferative phase, but not at the secretory 
phase of the menstrual cycle.  Significant differences (p<0.05, >3-fold) in the 
expression levels of these transcripts were found between the proliferative phases and 
the mid-/late-secretory phases (Fig. 1A).  Yet, no significant difference (p>0.05) was 
found in the expression of Olfm-3 or -4 transcripts in samples from different phases of 245 
the cycle (Fig. 1A). 
 The polyclonal antibody against Olfm-1 peptide was designed and raised from 
the rabbit.  Western blotting confirmed a specific band of the expected size (50-kDa) 
in the human endometrial lysate (Fig. 1B). Olfm-1 antibody could not be neutralized 
by Olfm-2 and -3 peptides.  The expression of Olfm-1 protein was higher in the 250 
proliferative phase of the menstrual cycle (Fig. 1C).  Immunohistochemistry on a 
paraffin-embedded human endometrial section identified strong Olfm-1 
immunoreactivity in the luminal and glandular epithelium, and a weaker signal in the 
stromal cells (Fig. 1D).  The signal could be nullified when the antibody was 
pre-absorbed with Olfm-1 peptide. 255 
 
Effect of ovarian stimulation on endometrial Olfm transcripts expression 
 The expression of Olfm transcripts in human endometria isolated from patients 
who underwent ovarian stimulation was compared with that from the patients from 
natural cycles.  Both Olfm-1 and -2 transcripts were found to be significantly 260 
(p<0.05) down-regulated in the stimulated group (Fig. 2).  Although there was a 
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slight increase in the expression of Olfm-4 transcript in the stimulated group, the 
difference was not statistically significant.  
 
Association of Olfm-1 and -2 expressions with serum estradiol, progesterone 265 
concentrations and estrogen receptor levels 
 Linear regression and Pearson correlation analysis were used to analyze the 
relationship of Olfm-1 and Olfm-2 transcripts with serum E2 and P4 concentrations 
and estrogen receptor α and β transcript levels (Fig. 3).  Serum E2 levels on hCG/LH 
day and P4 levels on hCG/LH+7 day were negatively correlated (p<0.05) with Olfm-2, 270 
but not Olfm-1 transcript levels.  Interestingly, estrogen receptor α was positively 
correlated (p<0.001) with both Olfm-1 and Olfm-2 levels.  Yet, estrogen receptor β 
was negatively correlated (p<0.01) with Olfm-2 but not Olfm-1 levels in the human 
endometrial samples. 
 275 
Effect of Olfm-1 on Spheroids-endometrial cell attachment assay 
rhOlfm-1 protein was expressed in E. coli as inclusion bodies.  Soluble 
rhOlfm-1 was obtained from the inclusion bodies after dialysis.  The binding of 
AlaxaFlour-labeled Olfm-1 was tested on JAr and Ishikawa cells.  It was found that 
both JAr and Ishikawa bound AlaxaFlour-labeled rhOlfm-1 (Fig. 4A).  To study how 280 
rhOlfm-1 modulates the attachment process in vitro, we used the 
spheroids-endometrial cells co-culture assay to study the attachment of spheroids onto 
Ishikawa cells.  Treatment of JAr cells for 48 hrs with rhOlfm-1 (0.1-10 µg/ml) did 
not affect the attachment rate onto Ishikawa cells (Fig. 4B).  However, there was a 
significant decrease (p<0.05) in the attachment rate when 10 µg/ml rhOlfm-1 was 285 
used to treat the Ishikawa cells (Fig. 4C).  When both JAr and Ishikawa cells were 
treated with rhOlfm-1 (0.1-10 µg/ml), there was a dose-dependent suppression of JAr 
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spheroids attachment onto the Ishikawa cells (Figure 4D).  The percentage of 
attachment decreased from 87% to 57% from 0.1 to 10 µg/ml Olfm-1 used.  
Similarly, the positive control MTX (5 µM) strongly suppressed the attachment of JAr 290 
onto the Ishikawa cells in all the experiments performed.  No significant decrease in 
attachment was observed when 1µg/ml BSA was used (97% vs 95%) when compared 
with the untreated control.  The average viability of the JAr and Ishikawa cells in all 
the groups after treatment was 90–94% as determined by Trypan Blue staining (data 
not shown). 295 
 
Effect of Olfm on E-cadherin and β-catenin expression in JAr and Ishikawa cells 
 To study whether Olfm regulates Wnt-signaling and extracellular matrix 
molecule expression in JAr and Ishikawa cells during the attachment process, the 
expression levels of β-catenin and E-cadherin were determined.  Treatment of the 300 
JAr or Ishikawa cells with Olfm-1 at 0-10µg/ml for 24 hrs and 28 hrs, respectively, 
did not affect E-cadherin and β-catenin expression (Fig. 5).  No observable change in 
β-actin expression was detected. 
 
305 
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Discussion 
 Previous microarray analysis suggested that down-regulation of Olfm-1 was 
found in the receptive endometrium (Horcajadas et al., 2004).  Our findings further 
suggested that both endometrial Olfm-1 and -2 transcripts, as well as Olfm-1 protein 
were down-regulated in the mid-secretory phase of the natural cycle and in patients 310 
who received ovarian stimulation for IVF treatment.  Moreover, recombinant human 
Olfm-1 protein binds to JAr and Ishikawa cells, and suppresses spheroid-endometrial 
cell attachment in vitro.  The suppressive effect was not associated with 
down-regulation of β-catenin or E-cadherin expression in neither Ishikawa nor JAr 
cells. 315 
 Both Olfm-1 and -2 transcripts were down-regulated in the secretory phase of 
the menstrual cycle when the serum estrogen and progesterone levels were high.  
Estrogen promotes, while progesterone suppresses the expression of ER and PR in the 
endometrial cells during the late proliferative phase and secretory phase of the 
menstrual cycle (Nisolle et al., 1994).  Since the expression of Olfm-1 and -2 320 
transcripts were positively correlated with the endometrial ERα level and high serum 
progesterone level suppresses ERα expression, it is possible that the steroid hormones 
may play both direct and indirect roles in regulating Olfm expression in vitro and in 
vivo.  Yet, no consensus estrogen responsive element (ERE) or the progesterone 
responsive element (PRE) were found in the Olfm proximal promoter regions, 325 
suggesting that the steroid regulation of Olfm-1 and -2 expression may be indirect. 
 Accumulating evidence suggested that high serum estradiol level advances 
endometrial development (Basir et al., 2001) not conducive to embryo implantation.  
Results from our laboratory demonstrated an advancement of gene expression profiles 
in patient with ovarian hyperstimulation (Liu et al., 2008).  However, Olfm 330 
transcripts remained at similar levels at the secretory phase of the natural cycle, 
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suggesting that down-regulation of Olfm expression by ovarian stimulation may not 
be associated with an advancement of endometrial development. 
 Fluorescent-labeled Olfm-1 strongly binds to JAr and Ishikawa cells.  It is 
possible that Olfm-1 may form a protective layer on the apical surface of the luminal 335 
epithelium, and its down-regulation in the peri-implantation period allows apposition 
and adhesion of the blastocysts onto the receptive endometrium while allowing the 
other molecules also to expose and interact with the embryo.  Yet, further 
investigations are needed to study if Olfm-1 binds to a specific receptor onto these 
cell lines and whether these bindings are specific to cells in reproductive tract. 340 
 A similar function has been proposed for MUC-1, a potent anti-adhesive 
extracellular matrix molecule in the endometrium (Meseguer et al., 1998).  MUC-1 
is down-regulated at the implantation site during the receptive period (Carson et al., 
1998).  Results form the JAr spheroids-Ishikawa cells attachment assay support our 
hypothesis that rhOlfm-1 may play a similar role to MUC-1 in embryo attachment.  345 
Interestingly, treatment of the JAr trophoblast cells with Olfm-1 had no effect on 
attachment, but treatment of the Ishikawa cells with Olfm-1 at a high concentration 
(10 µg/ml) significantly reduced the attachment rate, albeit that the Ishikawa cells 
express a detectable amount of Olfm protein (data not shown).  Importantly, when 
both JAr and Ishikawa cells were treated with Olfm-1, the change in the attachment 350 
rate became more prominent, showing a dose-dependent inhibition on attachment 
(from 97% to 57%). 
 Yet, results from this study suggested that further decrease in Olfm-1 
expression in the hyperstimulated endometrium is not associated with an increase in 
endometrial receptivity in vivo.  In fact, the expression of Olfm-1 transcript in the 355 
secretory phrase of natural cycle is low.  It is likely that down-regulation of other 
implantation-related (e.g. Wnt-signaling) signaling molecules may affect embryo 
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attachment in vivo.  For example, high level of DKK-1, a Wnt-signaling inhibitor 
which was commonly found in the endometria of ovarian stimulated patients, inhibits 
spheroids attachment in vitro (Liu et al., 2010).  Similarly, inactivation of nuclear 360 
Wnt-β-catenin signaling limits blastocyst competency for implantation (Xie et al., 
2008; Chen et al., 2009). 
 A differential expression of cadherins and intergrins may be involved in the 
successful attachment of an embryo onto the human endometrium (van der Linden et 
al., 1995).  A recent study demonstrated that an increased E-cadherin expression is 365 
associated with an increase in receptivity in non-receptive endometrial (AN3-CA) 
cells to BeWo spheroids attachment (Rahnama et al., 2009).  However, we did not 
observe detectable changes in β-catenin and E-cadherin expression in Ishikawa or JAr 
cells, although rhOlfm-1 binds to both cell types.  Therefore, it is likely that either 
Olfm-1 functions as a physical barrier for implantation or another unidentified 370 
signaling pathway may play an important role in the implantation process. 
 In summary, we first demonstrated the down-regulation of endometrial Olfm 
transcripts and protein at the secretory phase of the menstrual cycle.  Human 
recombinant Olfm-1 suppresses the attachment of spheroids onto endometrial 
Ishikawa cells and down-regulation of Olfm-1 during the receptive period may favor 375 
embryo attachment for successful implantation. 
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Figure Legends 
 
Figure 1 
The expression of olfactomedin (Olfm) transcripts in human endometrium.  The 485 
expression levels of (A) Olfm-1, -2, -3 and -4 transcripts were determined by 
real-time PCR. The values were the mean of log2 (RQ)±standard deviation of 
fold-induction of Olfm mRNA in multiple comparison calculated by the 2ΔΔCt method.  
a-b denotes significant difference (p<0.05) between groups. EP+MP: Early-Mid 
Proliferative, LP: Late Proliferative, ESMS: Early-Mid Secretory, LS: Late Secretory. 490 
(B) Sequence alignment of the Oflm peptides revealed higher homology between 
Olfm-1, -2 and -3 (blue).  Western blotting using Ishikawa, JAr and OE-E6/E7 cells 
showed a single band of about 50-kDa in size. The band could be neutralized with 
Olfm-1, but not Olfm-2 and -3 peptides.  β-actin protein was used as loading control. 
(C) Western blotting was performed for Olfm-1 expression in human endometrial 495 
samples (proliferative vs secretory phases). The protein loading was normalized with 
β-actin expression. (D) Immunohistochemical staining of Olfm-1 (brown staining) in 
human endometrium at the proliferative phase of the menstrual cycle.  Strong 
immunostaining was localized at the glandular and luminal epithelial cells. No signal 
was found when the antibody was pre-absorbed with blocking peptide. Scale bar = 500 
10µm. 
 
Figure 2 
The expression of olfactomedin in the endometrium of IVF patients. Human 
endometrial samples were taken from patients receiving IVF treatment.  The patients 505 
were divided into two groups: natural (n=15) and stimulated (n=32) cycles. The 
expression levels of Olfm-1, -2, -3 and -4 transcripts in these groups were determined 
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by real-time PCR analysis. * denotes significant difference (p<0.05) between groups. 
 
Figure 3 510 
Linear regression and Pearson correlation analysis on the expression of Olfm-1 
and Olfm-2 transcripts with serum E2 and P4 levels, and ERα and ERβ mRNA 
expression in endometrial tissues.  Pearson correlation of 47 endometrial samples 
was performed for Olfm-1 and Olfm-2 mRNA expression with the serum E2 level 
(pmol/L) at LH/hCG day, LH/hCG+7 day, serum P4 level (nmol/L) at LH/hCG+7 day, 515 
and tissue ERα and ERβ mRNA expression (fold-change normalized with 18S RNA).  
A p-value <0.05 denotes significant difference and the R value denotes the correlation 
coefficient. 
 
Figure 4 520 
Effect of Olfm-1 on the attachment of JAr spheroids to Ishikawa cells.  (A) 
Immunoflourescence staining of labeled rhOlfm-1.  Both JAr and Ishikawa bind to 
the labeled rhOlfm-1. (B) The effect of rhOlfm-1 treatment on JAr cells and the 
changes in attachment rate.  JAr cells treated with rhOlfm-1 protein were trypsinized 
and shaken for 24 hours to obtain spheroids of 60–200µm in size. The spheroids were 525 
put onto Ishikawa monolayer for an hour and the number of spheroids attached was 
determined as a percentage of the number of spheroids added.  The effect of MTX 
and/or BSA and Olfm-1 recombinant protein on the attachment of JAr spheroids was 
determined.  (C) The effect of rhOlfm-1 treatment on Ishikawa cells on the 
attachment rate in a co-culture study. (D) The effect of rhOlfm-1 treatment on both 530 
JAr and Ishikawa cells. Olfm-1 dose-dependently suppressed JAr attachment, while 
BSA at 1µg/ml did not affect spheroids attachment under the same culturing condition. 
The results were pooled from at least 4 independent experiments using more than 
 23 
2000 spheroids.  a-b, b-c and a-c denotes significant difference (p<0.01) from the 
control by One way ANOVA followed by Scheffe’s mean separation test. 535 
 
Figure 5 
Effect of Olfm-1 on the expression of E-cadherin and β-catenin in Ishikawa and 
JAr cells.  Ishikawa and JAr cells were treated with 0.1-10µg/ml rhOlfm-1 protein 
for 24 hrs and 48 hrs, respectively. The expression levels of E-cadherin and β-catenin 540 
proteins were determined by Western blotting. The protein loading was normalized by 
β-actin expression. 
 
AB C
D
Figure 1
- Olfm-1
- actin
Proliferative Secretory
LE
GE
SC
GE
Pre-absorbed 
Olfm-1 Ab
Olfm-1 Ab + Olfm-1 peptide
-actin Ab 
I
s
h
i
k
a
w
a
J
A
r
O
E
-
E
6
/
E
7
Olfm-1 Ab + Olfm-2 peptide
Olfm-1 Ab + Olfm-3 peptide
HuOlfm-1  238 PEGDNRVWYMDGYHNNRFVREYKSMVD
HuOlfm-2  224 PSADSRVWYMDGYYKGRRVLEFRTLGD
HuOlfm-3  228 SEKNNRVWYMDSYTNNKIVREYKSIAD
HuOlfm-4  281 QHPNKGLYWVAPLNTDGRLLEYYRLYN
Menstrual Phase
N
o
r
m
a
l
i
z
e
d
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
O
l
f
m
-
1
0
5
10
15
20
EP+MP       LP           ES           MS          LS
a
a
b
b
b
0
20
40
60
80
100
N
o
r
m
a
l
i
z
e
d
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
O
l
f
m
-
2
Menstrual Phase
EP+MP       LP           ES           MS          LS
a
a
a
b
b
N
o
r
m
a
l
i
z
e
d
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
O
l
f
m
-
3
Menstrual Phase
EP+MP       LP           ES           MS          LS
0
5
10
15
20
Olfm-2 Olfm-3Olfm-1
N
o
r
m
a
l
i
z
e
d
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
O
l
f
m
-
4
Menstrual Phase
EP+MP       LP           ES           MS          LS
0
10
20
30
40
50
Olfm-4
Figure 2
OLFM1 mRNA expression in normal & stimulated cycle 
Natural Cycle Stimulated Cycle
O
L
F
M
1
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
-
i
n
d
u
c
t
i
o
n
)
0
1
2
3
4
OLFM2 mRNA expression in normal & stimulated cycle 
Normal Cycle Stimulated Cycle
O
L
F
M
2
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
-
i
n
d
u
c
t
i
o
n
)
0
1
2
3
4
*
*
OLFM3 mRNA expression in normal & stimulated cycle 
Natural Cycle Stimulated Cycle
O
L
F
M
3
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
-
i
n
d
u
c
t
i
o
n
)
0
1
2
3
4
OLFM4 mRNA expression in normal & stimulated cycle 
X Data
Natural Cycle Stimulated Cycle
O
L
F
M
4
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
-
i
n
d
u
c
t
i
o
n
)
0
1
2
3
4
Olfm-1 Olfm-2
Olfm-3 Olfm-4
ER b
0 2 4 6
O
L
F
M
-
2
0
1
2
3
ER a
0 1 2 3 4 5
O
L
F
M
-
2
0
1
2
3
ER
Olfm-1 Olfm-2
E2 (hCG or LH)
0 20000 40000 60000
O
L
F
M
-
1
0
4
8
12
16
R = -0.222
P = 0.174
E2 (hCG+7 or LH+7)
0 10000 20000 30000 40000
O
L
F
M
-
1
0
4
8
12
16
R = -0.202
P = 0.215
P4 (hCG+7 or LH+7)
0 500 1000 1500 2000
O
L
F
M
-
1
0
4
8
12
16
R = -0.256
P = 0.115
ER a
0 1 2 3 4 5
O
L
F
M
-
1
-4
0
4
8
12
16
20
R = 0.582
P < 0.001
ER b
0 2 4 6
O
L
F
M
-
1
0
4
8
12
16
R = 0.00304
P = 0.985
E2 (hCG or LH)
0 20000 40000 60000
O
L
F
M
-
2
0
1
2
3
R = -0.344 
P < 0.05
E2 (hCG+7 or LH+7)
0 10000 20000 30000
O
L
F
M
-
2
0
1
2
3
R = -0.247
P = 0.124
P4 (hCG+7 or LH+7)
0 1000 2000
O
L
F
M
-
2
0
1
2
3
R = -0.352 
P < 0.05
R = 0.516
P < 0.001
R = -0.394
P < 0.01
ER
ER R
E2 (hCG/LH) E2 (hCG/LH)
E2 (hCG/LH+7) E2 (hCG/LH+7)
P4 (hCG/LH+7) P  ( CG/LH+ )
Olfm-1 Olfm-2
Figure 3
020
40
60
80
100
120
Figure 4
A
C
J
A
r
I
s
h
i
k
a
w
a
rhOlfm
B
0
20
40
60
80
100
120
Control MTX
5µM
A
t
t
a
c
h
m
e
n
t
 
(
%
)
b
a a a a,c
b,c
D
A
t
t
a
c
h
m
e
n
t
 
(
%
)
0
20
40
60
80
100
120
a
b
a a a
Control MTX
5µM
0.1 1 10
rhOlfm (µg/ml)
A
t
t
a
c
h
m
e
n
t
 
(
%
)
a
b
a
c
a,c
Control BSA
1 µg/ml
MTX
5µM
0.1 1 10
rhOlfm (µg/ml)
a,c
0.1 1 10
rhOlfm (µg/ml)
JAr
JAr + IshikawaIshikawa
BSA
1 µg/ml
Olfm-1 (g/ml)
Con       0.1       1        10
Ishikawa cells
(24hr)
Figure 5
E-cadherin (115 kDa)
-catenin (92 kDa)
-actin (42 kDa)
E-cadherin (115 kDa)
-catenin (92 kDa)
-actin (42 kDa)
JAr cells
(48hr)
